<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.28996/2618-9801-2018-4-394-403</article-id><article-id custom-type="elpub" pub-id-type="custom">nid-353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ШКОЛА НЕФРОЛОГА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EDUCATIONAL MATERIALS</subject></subj-group></article-categories><title-group><article-title>Терапевтический плазмообмен в интенсивной терапии и интенсивной нефрологии</article-title><trans-title-group xml:lang="en"><trans-title>Therapeutic plasma exchange in intensive care and intensive nephrology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветшева</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetsheva</surname><given-names>M. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лосс</surname><given-names>К. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Loss</surname><given-names>K. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подкорытова</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Podkorytova</surname><given-names>O. L.</given-names></name></name-alternatives><email xlink:type="simple">o-podkorytova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебедьков</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedkov</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Столбова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Stolbova</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Назарова</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Nazarova</surname><given-names>I. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткаченко</surname><given-names>Н. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachenko</surname><given-names>N. Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарнопольский</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarnopolskiy</surname><given-names>R. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлева</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovleva</surname><given-names>I. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ ВПО Первый МГМУ им. И.М. Сеченова МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ "ГКБ № 52 Департамента здравоохранения г. Москвы"</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow City Hospital № 52</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>12</day><month>08</month><year>2024</year></pub-date><volume>20</volume><issue>4</issue><fpage>394</fpage><lpage>403</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ветшева М.С., Лосс К.Э., Подкорытова О.Л., Лебедьков Е.В., Столбова И.А., Назарова И.Н., Ткаченко Н.Я., Тарнопольский Р.А., Яковлева И.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ветшева М.С., Лосс К.Э., Подкорытова О.Л., Лебедьков Е.В., Столбова И.А., Назарова И.Н., Ткаченко Н.Я., Тарнопольский Р.А., Яковлева И.И.</copyright-holder><copyright-holder xml:lang="en">Vetsheva M.S., Loss K.E., Podkorytova O.L., Lebedkov E.V., Stolbova I.A., Nazarova I.N., Tkachenko N.Y., Tarnopolskiy R.A., Yakovleva I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/353">https://journal.nephro.ru/jour/article/view/353</self-uri><abstract><p>Терапевтический плазмообмен (ПО) - это процедура, которая представляет собой процесс удаления большого объема плазмы с последующим замещением, при этом происходит удаление различных биологически активных веществ, которые оказывают патологическое воздействие на организм пациента. Плазмообмен при некоторых заболеваниях является одним из звеньев патогенетической терапии (АНКА-ассоциированный системный васкулит, антифосфолипидный синдром, синдром Гудпасчера, тромботическая микроангиопатия и др.), удаляя циркулирующие иммунные комплексы, повреждающие ткани и органы-мишени, восстанавливает нарушенную систему свертывания крови. В 2016 году вышли последние практические рекомендации американского общества афереза, в котором ведущие специалисты в области аферезной терапии на основании анализа многочисленных клинических исследований, дают врачам всех специальностей, занимающихся экстракорпоральной детоксикацией, четкие рекомендации по применению аферезных технологий. Также разработаны 4 категории показаний и противопоказаний, оценивающих пользу проведения процедур афереза для конкретной нозологии. Внесен ряд новых заболеваний, таких как атопический (нейро) дерматит (атопическая экзема), кардиальная неонатальная волчанка, энцефалопатия Хашимото, HELLP синдром, при которых ПО является одним из ведущих лечебных мероприятий наряду с цитостатической и глюкокортикостероидой терапией. Однако остается ряд заболеваний, при котором использование ПО остается спорным, как например сепсис, это заставляет проводить дальнейшие исследования в этом направлении.</p></abstract><trans-abstract xml:lang="en"><p>Therapeutic plasma exchange (PE) is a procedure of removing and replacing a large volume of plasma with various biologically active substances that have a pathological effect on the patient. Plasma exchange in some diseases is one of the components of pathogenetic therapy (ANCA-associated systemic vasculitis, antiphospholipid syndrome, Goodpasture’s syndrome, thrombotic microangiopathy, etc.). PE removes circulating immune complexes damaging tissues and organs and restores the coagulation system. In the practical recommendations of the American Apheresis Society (2016) leading experts in the field of apheresis therapy, based on an analysis of numerous clinical studies, gave clear recommendations to use the apheresis technologies for extracorporeal detoxification. Also 4 categories of indications and contraindications, assessing the benefits of carrying out apheresis procedures for a specific nosology were specified. A number of new diseases have been introduced, such as atopic (neuro) dermatitis (atopic eczema), cardiac neonatal lupus, Hashimoto encephalopathy, HELLP syndrome, in which PE is one of the leading therapeutic approaches as well as cytotoxic and glucocorticosteroid therapy. However, the use of plasma exchange in the treatment of some diseases remains controversial, for example, sepsis. So further research is needed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>терапевтический плазмообмен</kwd><kwd>аутоантитела</kwd><kwd>иммуноглобулины</kwd><kwd>факторы свертывания</kwd><kwd>сепсис</kwd><kwd>полиорганная недостаточность</kwd><kwd>therapeutic plasma exchange</kwd><kwd>autoantibodies</kwd><kwd>immunoglobulins</kwd><kwd>coagulation factors</kwd><kwd>sepsis</kwd><kwd>multiorgan failure</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Burgstaler EA: Current instrumentation for apheresis. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL, eds. Apheresis: Principles and Practice. 3rd Ed. Bethesda, MD: AABB Press. 2010.95-130.</mixed-citation><mixed-citation xml:lang="en">Burgstaler EA: Current instrumentation for apheresis. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL, eds. Apheresis: Principles and Practice. 3rd Ed. Bethesda, MD: AABB Press. 2010.95-130.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Goto H, Matsuo H, Nakane S. Plasmapheresis affects Thelper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher. 2001.5:494-496.</mixed-citation><mixed-citation xml:lang="en">Goto H, Matsuo H, Nakane S. Plasmapheresis affects Thelper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher. 2001.5:494-496.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan AA: Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis (RPGN). Ther Apher. I, 1997. 255-259.</mixed-citation><mixed-citation xml:lang="en">Kaplan AA: Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis (RPGN). Ther Apher. I, 1997. 255-259.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Luca G, Lugaresi A, Iarlori C. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1999.95:190-194.</mixed-citation><mixed-citation xml:lang="en">De Luca G, Lugaresi A, Iarlori C. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1999.95:190-194.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Flaum MA, Cuneo RA, Appelbaum FR. The hemostatic imbalance of plasma-exchange transfusion. Blood. 1979.54:694-702.</mixed-citation><mixed-citation xml:lang="en">Flaum MA, Cuneo RA, Appelbaum FR. The hemostatic imbalance of plasma-exchange transfusion. Blood. 1979.54:694-702.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Orlin JB, Berkman EM: Partial plasma exchange using albumin replacement: Removal and recovery of normal plasma constituents. Blood. 1980.56:1055-1059.</mixed-citation><mixed-citation xml:lang="en">Orlin JB, Berkman EM: Partial plasma exchange using albumin replacement: Removal and recovery of normal plasma constituents. Blood. 1980.56:1055-1059.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chirnside A, Urbaniak SJ, Prowse CV. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981. 48:627-634.</mixed-citation><mixed-citation xml:lang="en">Chirnside A, Urbaniak SJ, Prowse CV. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981. 48:627-634.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Flaum MA, Cuneo RA, Appelbaum FR. The hemostatic imbalance of plasma-exchange transfusion. Blood. 1979.54:694-702.</mixed-citation><mixed-citation xml:lang="en">Flaum MA, Cuneo RA, Appelbaum FR. The hemostatic imbalance of plasma-exchange transfusion. Blood. 1979.54:694-702.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Clark WF, Stewart AK, Rock GA. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med. 2005.143:777-784.</mixed-citation><mixed-citation xml:lang="en">Clark WF, Stewart AK, Rock GA. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med. 2005.143:777-784.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen S, Freeman T: Metabolic heterogeneity of human gamma globulin. Biochem J. 1960.76:475-487</mixed-citation><mixed-citation xml:lang="en">Cohen S, Freeman T: Metabolic heterogeneity of human gamma globulin. Biochem J. 1960.76:475-487</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Joseph Schwartz, Anand Padmanabhan, Nicole Aqui, Rasheed A. Balogun, Laura Connelly-Smith, Meghan Delaney, Nancy M. Dunbar, Volker Witt, Yanyun Wu, and Beth H. Shaz. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis DOI 10.1002/jca. 31:149-162 (2016) American Society for Apheresis.</mixed-citation><mixed-citation xml:lang="en">Joseph Schwartz, Anand Padmanabhan, Nicole Aqui, Rasheed A. Balogun, Laura Connelly-Smith, Meghan Delaney, Nancy M. Dunbar, Volker Witt, Yanyun Wu, and Beth H. Shaz. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis DOI 10.1002/jca. 31:149-162 (2016) American Society for Apheresis.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan А.А., MD. Therapeutic Plasma Exchange: Core Curriculum 2008. American Journal of Kidney Diseases. 2008.52(6):1180-1196.</mixed-citation><mixed-citation xml:lang="en">Kaplan А.А., MD. Therapeutic Plasma Exchange: Core Curriculum 2008. American Journal of Kidney Diseases. 2008.52(6):1180-1196.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013.369:2525-2534.</mixed-citation><mixed-citation xml:lang="en">Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013.369:2525-2534.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Huang YK, Tan DM, Xie YT, Fan XG, Huang Y, Liu ZB, Li SL. Randomized controlled study of plasma exchange combined with molecular adsorbent re-circulating system for the treatment of liver failure complicated with hepatic encephalopathy. Hepatogastroenterology 2012.59:1323-1326.</mixed-citation><mixed-citation xml:lang="en">Huang YK, Tan DM, Xie YT, Fan XG, Huang Y, Liu ZB, Li SL. Randomized controlled study of plasma exchange combined with molecular adsorbent re-circulating system for the treatment of liver failure complicated with hepatic encephalopathy. Hepatogastroenterology 2012.59:1323-1326.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li M-Q, Li J-Q, Shi Z-X, Xu J-Y, Zhang Z, Lu F, Li L, Xu YJ, Mo X, Lu B, Wang X-M, Ma L-L, Zhang X-J, Cheng S-L. Efficacy of various combined blood purification techniques for treating patients with non-viral acute liver failure. Cell Biochem Biophys. 2014.68:571-575.</mixed-citation><mixed-citation xml:lang="en">Li M-Q, Li J-Q, Shi Z-X, Xu J-Y, Zhang Z, Lu F, Li L, Xu YJ, Mo X, Lu B, Wang X-M, Ma L-L, Zhang X-J, Cheng S-L. Efficacy of various combined blood purification techniques for treating patients with non-viral acute liver failure. Cell Biochem Biophys. 2014.68:571-575.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring PN, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen BA, Antoniades CG, Wendon J. Highvolume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016.64:69-78.</mixed-citation><mixed-citation xml:lang="en">Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring PN, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen BA, Antoniades CG, Wendon J. Highvolume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016.64:69-78.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barre syndrome. Arch Dis Child Educ Pract Ed. 2007.92:161-168.</mixed-citation><mixed-citation xml:lang="en">Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barre syndrome. Arch Dis Child Educ Pract Ed. 2007.92:161-168.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barrе syndrome: incidence and mortality rates in US hospitals. Neurology. 2008.70:1608-1613.</mixed-citation><mixed-citation xml:lang="en">Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barrе syndrome: incidence and mortality rates in US hospitals. Neurology. 2008.70:1608-1613.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barre syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis. 2010.12:55-61.</mixed-citation><mixed-citation xml:lang="en">Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barre syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis. 2010.12:55-61.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2012.7:CD001798.</mixed-citation><mixed-citation xml:lang="en">Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2012.7:CD001798.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North Am. 2015. 41:93-108.</mixed-citation><mixed-citation xml:lang="en">Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North Am. 2015. 41:93-108.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sneller MV, Hu Z, Langford CA, A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012.64:835-842.</mixed-citation><mixed-citation xml:lang="en">Sneller MV, Hu Z, Langford CA, A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012.64:835-842.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, BelenottiP, de Saint-Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Diot E, Lazaro E, Bridoux F, Zenone T, Carrat F, Hermine O, LegerJM, Mariette X, Senet P, Plaisier E, Cacoub P. Managementof noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012.119:5996-6004.</mixed-citation><mixed-citation xml:lang="en">Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, BelenottiP, de Saint-Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Diot E, Lazaro E, Bridoux F, Zenone T, Carrat F, Hermine O, LegerJM, Mariette X, Senet P, Plaisier E, Cacoub P. Managementof noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012.119:5996-6004.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci. 2010.42:247-251.</mixed-citation><mixed-citation xml:lang="en">Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci. 2010.42:247-251.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, PieterograndeM, Ferri C, Mascia MT Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli PK Gabrielli A, FilippiniD, Perrella O, Miglairesi S, Galli M, Bombardieri S, MontiG. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012.64:843-853.</mixed-citation><mixed-citation xml:lang="en">De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, PieterograndeM, Ferri C, Mascia MT Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli PK Gabrielli A, FilippiniD, Perrella O, Miglairesi S, Galli M, Bombardieri S, MontiG. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012.64:843-853.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Stefanutti C, Vivensio A, DiGiamcomo S, Labbadia G, MazzaF, D’Alessandri G, Ferraro PM, Masala C. Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia. J ClinApher. 2009.24:241-246.</mixed-citation><mixed-citation xml:lang="en">Stefanutti C, Vivensio A, DiGiamcomo S, Labbadia G, MazzaF, D’Alessandri G, Ferraro PM, Masala C. Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia. J ClinApher. 2009.24:241-246.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Erkurt MA, Berber I, Berktas HB, Kuku I, Kaya E, Koroglu M, Nizam I, Bakırhan FA, Ozgul M. A life-saving therapy in Class I HELLP syndrome: therapeutic plasma exchange. Transfus Apher Sci. 2015.52:194-198.</mixed-citation><mixed-citation xml:lang="en">Erkurt MA, Berber I, Berktas HB, Kuku I, Kaya E, Koroglu M, Nizam I, Bakırhan FA, Ozgul M. A life-saving therapy in Class I HELLP syndrome: therapeutic plasma exchange. Transfus Apher Sci. 2015.52:194-198.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Martin JN. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia). Int J Gynaecol Obstet. 2013.121:202-207.</mixed-citation><mixed-citation xml:lang="en">Martin JN. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia). Int J Gynaecol Obstet. 2013.121:202-207.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Simetka O, Klat J, Gumelec J, Dolezalkova E, Salounova D, Kаcerovsky M. Early identification of women with HELLP syndrome who need plasma exchange after delivery. Transfus Apher Sci. 2015.52:54-59.</mixed-citation><mixed-citation xml:lang="en">Simetka O, Klat J, Gumelec J, Dolezalkova E, Salounova D, Kаcerovsky M. Early identification of women with HELLP syndrome who need plasma exchange after delivery. Transfus Apher Sci. 2015.52:54-59.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost. 2012.38:333-338.</mixed-citation><mixed-citation xml:lang="en">Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost. 2012.38:333-338.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Berman H, Rodr_ıguez-Pint_o I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013.12:1085-1090.</mixed-citation><mixed-citation xml:lang="en">Berman H, Rodr_ıguez-Pint_o I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013.12:1085-1090.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Marson P, Bagatella P, Bortolati M, Tison T, De Silvestro G, Fabris F, Pengo V, Ruffatti A. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med. 2008.264:201-203.</mixed-citation><mixed-citation xml:lang="en">Marson P, Bagatella P, Bortolati M, Tison T, De Silvestro G, Fabris F, Pengo V, Ruffatti A. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med. 2008.264:201-203.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost. 2012.38:333-338.</mixed-citation><mixed-citation xml:lang="en">Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost. 2012.38:333-338.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Espinosa G, Rodr_ıguez-Pint_o I, Gomez-Puerta JA, Pons-Estel G, Cervera R; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013.42:417-423.</mixed-citation><mixed-citation xml:lang="en">Espinosa G, Rodr_ıguez-Pint_o I, Gomez-Puerta JA, Pons-Estel G, Cervera R; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013.42:417-423.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci. 2005.33:11-17.</mixed-citation><mixed-citation xml:lang="en">Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci. 2005.33:11-17.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology 2014 (1):444-449.</mixed-citation><mixed-citation xml:lang="en">Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology 2014 (1):444-449.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Barz, D., Budde, U. &amp; Hellstern, P. Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thrombosis Research. 2002.107 (1):23-S27.</mixed-citation><mixed-citation xml:lang="en">Barz, D., Budde, U. &amp; Hellstern, P. Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thrombosis Research. 2002.107 (1):23-S27.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Loirat, C., Noris, M. &amp; Fremeaux Bacchi. Complement and the atypical hemolytic uremic syndrome in children. Pediatric Nephrology. 2008. 23:1957-1972.</mixed-citation><mixed-citation xml:lang="en">Loirat, C., Noris, M. &amp; Fremeaux Bacchi. Complement and the atypical hemolytic uremic syndrome in children. Pediatric Nephrology. 2008. 23:1957-1972.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Von Baeyer, H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Therapeutic Apheresis. 2002.6: 320-328.</mixed-citation><mixed-citation xml:lang="en">Von Baeyer, H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Therapeutic Apheresis. 2002.6: 320-328.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ariceta, G., Besbas, N., Johnson, S.,Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C.M., Van de Kar, N., Vandewalle, J. &amp; Zimmerhackl, L.B. Guideline for the investigation and initial therapy of diarrhea negative hemolytic uremic syndrome. Pediatric Nephrology. 2009. 24:687-696.</mixed-citation><mixed-citation xml:lang="en">Ariceta, G., Besbas, N., Johnson, S.,Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C.M., Van de Kar, N., Vandewalle, J. &amp; Zimmerhackl, L.B. Guideline for the investigation and initial therapy of diarrhea negative hemolytic uremic syndrome. Pediatric Nephrology. 2009. 24:687-696.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C.,Bresin, E., Cassis, L., Gamba, S., Porrati, F.,Bucchioni, S., Monteferrante, G., Fang, C.J., Liszewski, M.K., Kavanagh, D.,Atkinson, J.P. &amp; Remuzzi, G. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006.108:1267-1279.</mixed-citation><mixed-citation xml:lang="en">Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C.,Bresin, E., Cassis, L., Gamba, S., Porrati, F.,Bucchioni, S., Monteferrante, G., Fang, C.J., Liszewski, M.K., Kavanagh, D.,Atkinson, J.P. &amp; Remuzzi, G. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006.108:1267-1279.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan AA: Therapeutic apheresis for cancer related hemolytic uremic syndrome. Ther Apher. 2000.4:201-206.</mixed-citation><mixed-citation xml:lang="en">Kaplan AA: Therapeutic apheresis for cancer related hemolytic uremic syndrome. Ther Apher. 2000.4:201-206.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Jayne, D.R., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C.O., Sinico, R.A. &amp; Stegeman, C.A. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Journal of the American Society of Nephrology: JASN. 2007.18:2180-2188.</mixed-citation><mixed-citation xml:lang="en">Jayne, D.R., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C.O., Sinico, R.A. &amp; Stegeman, C.A. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Journal of the American Society of Nephrology: JASN. 2007.18:2180-2188.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh M, Merkel PA, Jayne D. The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated vasculitis [abstract]. Arthritis Rheumatol. 2018.70 (10).</mixed-citation><mixed-citation xml:lang="en">Walsh M, Merkel PA, Jayne D. The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated vasculitis [abstract]. Arthritis Rheumatol. 2018.70 (10).</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Baruch D: Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 2007.35:2375-82.</mixed-citation><mixed-citation xml:lang="en">Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Baruch D: Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 2007.35:2375-82.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Busund R, Koukline V, Utrobin U, Nedashkovsky E: Plasmapheresis in severe sepsis and septic shock: a prospective, randomized, controlled trial. Intensive Care Med. 2002.28:1434-9.</mixed-citation><mixed-citation xml:lang="en">Busund R, Koukline V, Utrobin U, Nedashkovsky E: Plasmapheresis in severe sepsis and septic shock: a prospective, randomized, controlled trial. Intensive Care Med. 2002.28:1434-9.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ: Continuous plasma filtration in sepsis syndrome. Plasmafiltration in sepsis study group. Crit Care Med. 1999.27:2096-104.</mixed-citation><mixed-citation xml:lang="en">Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ: Continuous plasma filtration in sepsis syndrome. Plasmafiltration in sepsis study group. Crit Care Med. 1999.27:2096-104.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J, Carcillo JA. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008.36:2878-2887.</mixed-citation><mixed-citation xml:lang="en">Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J, Carcillo JA. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008.36:2878-2887.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Surviving Sepsis Campaign, Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Moreno R. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013.41:580-637.</mixed-citation><mixed-citation xml:lang="en">Surviving Sepsis Campaign, Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Moreno R. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013.41:580-637.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Bellomo R, Honoré PM, Matson J, Ronco C, Winchester J: Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs. 2005.28:450-458.</mixed-citation><mixed-citation xml:lang="en">Bellomo R, Honoré PM, Matson J, Ronco C, Winchester J: Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs. 2005.28:450-458.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
